Specific Biomarkers for Detection of Cervical Cancer Cells Using Flow Cytometry

使用流式细胞术检测宫颈癌细胞的特异性生物标志物

• 批准号: 7186773
• 负责人: JOSEPH PAUL ROBINSON
• 金额: $ 18.59万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-18 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7186773
• 关键词: Abnormal Cell; Address; Adopted; Affinity; Antibodies; Area; Biological Markers; Biopsy; Biotinylation; Blood Cells; CDKN2A gene; Cancerous; Categories; Cell Count; Cell Separation; Cells; Cervical; Cervical Cancer Screening; Clinical; Color; Condition; Cytology; Cytopathology; D Cells; Data; Death Rate; Detection; Developed Countries; Developing Countries; Devices; Diagnostic Procedure; Disease; Dissociation; Event; Failure; Flow Cytometry; Fluorescence; Fluorescent Antibody Technique; Future; Goals; Hela Cells; Image; Imaging technology; Immunofluorescence Immunologic; Immunohistochemistry; Incidence; Individual; Lead; Lesion; Liquid substance; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Measurement; Measures; Methods; Microscopic; Modification; Mus; Noise; Normal Cell; Numbers; Pap smear; Phycoerythrin; Population; Premalignant; Preparation; Procedures; Process; Rate; Research Personnel; Sampling; Screening procedure; Sensitivity and Specificity; Signal Transduction; Sorting - Cell Movement; Specimen; Staining method; Stains; Suspension substance; Suspensions; Techniques; Technology; Testing; Time; Validation; Visual; Woman; allophycocyanin; base; cancer cell; cell fixation; experience; fluorescence imaging; improved; instrument; instrumentation; malignant breast neoplasm; mortality; novel; novel strategies; programs; systems research; technology development

DESCRIPTION (provided by applicant): Cervical cancer is second to breast cancer as the most common form of malignancy in both incidence and mortality for women worldwide. The pap smear test and liquid-based cytology have been adopted as population-wide cervical cancer screening programs in the U.S. and other developed countries. In the US, this screening program has led to a remarkable reduction in the incidence and mortality rate of cervical cancer, from 26,000 in 1941 to 4,600 in 2000. However, the current method of cervical cancer screening is still subjective and labor intensive in the detection of abnormal cells from large number of normal cells. This application proposes a new approach of involving specific biomarkers and high throughput flow cytometry for the detection of rare abnormal cells. Abnormal cells will be captured and separated from normal cells using flow sorting and based on their expression levels of precancerous biomarkers. The development of this technology could lead to a high throughput, biomarker driven clinical device for routine cervical cancer screening in the future.

描述（由申请人提供）：宫颈癌是仅次于乳腺癌的最常见的恶性肿瘤，在全球范围内的妇女的发病率和死亡率。在美国和其他发达国家，巴氏涂片检查和液基细胞学检查已被用作全民宫颈癌筛查计划。在美国，这项筛查计划使宫颈癌的发病率和死亡率显著下降，从1941年的26，000人下降到2000年的4，600人。然而，目前的宫颈癌筛查方法在从大量正常细胞中检测异常细胞方面仍然是主观和劳动密集型的。本申请提出了一种涉及特异性生物标志物和高通量流式细胞术用于检测罕见异常细胞的新方法。异常细胞将使用流式分选并根据其癌前生物标志物的表达水平被捕获并与正常细胞分离。这项技术的发展可能会导致高通量，生物标志物驱动的临床设备，用于未来的常规宫颈癌筛查。